2.34
+0.43%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About MacroGenics
From its filings with the US Securities and Exchange Commission
MacroGenics is based in Rockville, Maryland and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker MGNX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $149.5m and a net loss of $74.6m. At that date it held total assets of $256.8m and shareholders' equity of $55.6m. By business, Collaborative and other agreements brought in 58.3% of revenue, followed by Contract manufacturing at 35.2% and Royalty revenue at 6.5%.
We currently have three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. We are also actively developing preclinical-stage ADC and next generation T-cell engager programs.
We and our partners are developing or commercializing product candidates for which we retain certain economic rights. These include three products approved by the FDA: ZYNYZ® (retifanlimab-dlwr), an anti-PD-1 monoclonal antibody (mAb) that we out-licensed; MARGENZA® (margetuximab-cmkb), an anti-HER2 mAb that we sold to a partner; and TZIELD® (teplizumab-mzwv), an anti-CD3 mAb that we sold to a partner. We are also collaborating with Gilead Sciences, Inc. (Gilead) on the development of MGD024, a bispecific DART molecule targeting CD123 and CD3 that utilizes our next-generation T-cell engager technology, as well as two additional undisclosed pre-clinical DART and TRIDENT molecule development programs.
Quoted from its 10-K, filed 9 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 10 Oct 2013
- Employees
- 293
- Website
- macrogenics.com ↗
- Head office
- 9704 MEDICAL CENTER DRIVE, Rockville, MD, 20850
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. William HeidenIndependent Chairman of the Board$304,716
- Mr. Eric RisserPresident, Chief Executive Officer, Director, since 2009$1.9m
- Mr. James KarrelsChief Financial Officer, Senior Vice President, Corporate Secretary$2.4m
- Dr. Ezio BonviniSenior Vice President - Research, Chief Scientific Officer$2.3m
- Mr. Jeffrey PetersSenior Vice President, General Counsel, Corporate Compliance Officer
- Dr. Stephen EckSenior Vice President - Clinical Development, Chief Medical Officer$2.6m
- Mr. Thomas SpitznagelSenior Vice President - Technical Operations$1.9m
- Ms. Beth SmithVice President, Controller, Treasurer
- Ms. Meenu Chhabra KarsonIndependent Director$150,689
- Dr. Karen FerranteIndependent Director$145,633
- Mr. Edward HurwitzIndependent Director$145,633
- Mr. Scott JacksonIndependent Director$151,571
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 78
- Environment
- 73
- Social
- 87
- Governance
- 75
- Women in the workforce
- 59%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong research and development capabilities in the field of biotechnology.
- Well-established strategic partnerships with leading pharmaceutical companies.
- Robust intellectual property portfolio with numerous patents.
- Skilled and experienced management team with expertise in the biotech industry.
Weaknesses
- Heavy reliance on a limited number of drug candidates in the pipeline.
- Vulnerability to regulatory challenges and delays in drug approvals.
- High operating costs associated with the development and clinical trials of new drugs.
- Limited market presence compared to larger pharmaceutical competitors.
Opportunities
- Growing demand for novel biologic therapies in the healthcare market.
- Potential expansion into international markets to increase revenue streams.
- Collaborations with academic institutions for research advancements and talent acquisition.
- Increasing investments in precision medicine and personalized healthcare.
Threats
- Intense competition from other biotech and pharmaceutical companies.
- Rising costs of research and development, potentially impacting profitability.
- Regulatory changes and stricter compliance requirements for drug development and commercialization.
- Uncertainties associated with the outcome of clinical trials and drug efficacy.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.